Aidan Power

Dr. Aidan Power


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MTMartin Tolar
Martin Tolar
JHJohn Hey
John Hey
APAidan Power
Aidan Power
SASusan Abushakra
Susan Abushakra
A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer’s disease (AD). Recent late-stage trials in AD that have evaluated agents targeting distinct species of Aβ provide compelling evidence that inhibition of Aβ oligomer toxicity represents an effective approach to slow or stop disease progression: (1) only agents that target soluble Aβ oligomers show clinical efficacy in AD patients; (2) clearance of amyloid plaque does not correlate with clinical improvements; (3) agents that predominantly target amyloid monomers or plaque failed to show clinical effects; and (4) in positive trials, efficacy is greater in carriers of the ε4 allele of apolipoprotein E (APOE4), who are known to have higher brain concentrations of Aβ oligomers. These trials also show that inhibiting Aβ neurotoxicity leads to a reduction in tau pathology, suggesting a pathogenic sequence of events where amyloid toxicity drives an increase in tau formation and deposition. The late-stage agents with positive clinical or biomarker data include four antibodies that engage Aβ oligomers (aducanumab, lecanemab, gantenerumab, and donanemab) and ALZ-801, an oral agent that fully blocks the formation of Aβ oligomers at the clinical dose.

Verified
Journal Article
Open access
PDF file
MTMartin Tolar
Martin Tolar
JHJohn Hey
John Hey
APAidan Power
Aidan Power
SASusan Abushakra
Susan Abushakra
New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer’s disease (AD) and other age-related neurodegenerative disorders. We propose a unifying single toxin theory of brain neurodegeneration that identifies new targets and approaches to the development of disease-modifying treatments. An extensive body of genetic evidence suggests soluble aggregates of beta-amyloid (Aβ) as the primary neurotoxin in the pathogenesis of AD. New insights from fluid biomarkers, imaging, and clinical studies provide further evidence for the decisive impact of toxic Aβ species in the initiation and progression of AD. Understanding the distinct roles of soluble and insoluble amyloid aggregates on AD pathogenesis has been the key missing piece of the Alzheimer’s puzzle. Data from clinical trials with anti-amyloid agents and recent advances in the diagnosis of AD demonstrate that the driving insult in biologically defined AD is the neurotoxicity of soluble Aβ aggregates, called oligomers and protofibrils, rather than the relatively inert insoluble mature fibrils and amyloid plaques. Amyloid oligomers appear to be the primary factor causing the synaptic impairment, neuronal stress, spreading of tau pathology, and eventual cell death that lead to the clinical syndrome of AD dementia. All other biochemical effects and neurodegenerative changes in the brain that are observed in AD are a response to or a downstream effect of this initial toxic insult by oligomers. Other neurodegenerative disorders follow a similar pattern of pathogenesis, in which normal brain proteins with important biological functions become trapped in the aging brain due to impaired clearance and then misfold and aggregate into neurotoxic species that exhibit prion-like behavior. These aggregates then spread through the brain and cause disease-specific neurodegeneration. Targeting the inhibition of this initial step in neurodegeneration by blocking the misfolding and aggregation of healthy proteins has the potential to slow or arrest disease progression, and if treatment is administered early in the course of AD and other neurodegenerative disorders, it may delay or prevent the onset of clinical symptoms.

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
APAidan Power
Aidan Power
SASusan Abushakra
Susan Abushakra
DWDavid Watson
David Watson
APAnton P. Porsteinsson
Anton P. Porsteinsson
MSMarwan N. Sabbagh
Marwan N. Sabbagh
MTMartin Tolar
Martin Tolar
Background: Valiltramiprosate (ALZ‐801) is an oral inhibitor of amyloid oligomer formation. Tramiprosate (active agent in ALZ‐801) had shown promising efficacy signals with favorable safety in ∼1300 APOE4 carriers with AD, with no observed ARIA‐E. This trial evaluated Valiltramiprosate in APOE4/4 homozygotes with Early AD. Method: This 78‐week double‐blind, placebo‐controlled, two‐arm trial that randomized 325 homozygotes (162 to placebo, 163 to 265 mg BID), stratified by MCI (MMSE 27‐30) or Mild AD (MMSE 22‐26). MRI (1.5/3 Tesla) were conducted every 26 weeks and analyzed by Clario Inc. The clinical outcomes were ADAS‐Cog13 (primary), CDR‐SB (key secondary) and DAD (disability assessment for dementia, secondary). Hippocampal volume (HV) was the main imaging outcome. MMRM was the primary analysis model. Result: Safety population ( N =325) was 51% females, 90% Caucasian, mean age 68 years, MMSE 25.6, 39% with MCI (MMSE 27‐30) and 30% with baseline microhemorrhages and/or siderosis. In the full analysis set ( N =320), the placebo‐adjusted least‐square mean (LSM) difference in change from baseline (CBL) on ADAS‐Cog13 favored drug non‐significantly (delta=‐0.50; p =0.61, 11% vs placebo CBL); CDR‐SB and DAD numerically favored drug by 23% and 29%, but HV favored drug significantly (74 mm 3 , nominal p =0.017, 18% less atrophy ). Prespecified Mild AD showed small nonsignificant clinical effects favoring placebo, but showed numerical benefit on HV (51mm 3 , 12% p = 0.115). In prespecified MCI, all outcomes favored drug (nominal p ‐values): ADAS‐Cog13= ‐2.14 ( p =0.041; 52%); CDR‐SB= ‐0.65 ( p =0.053, 104%); DAD= 6.09 ( p =0.016, 96%); and HV= 108 mm 3 ( p = 0.004, 26% less atrophy). Nausea (mostly mild) was the most common adverse event; incidence of ARIA‐E was the same as placebo. Conclusion: In the overall population, ADAS‐Cog13 did not achieve significance, but the hippocampus showed significant 18% slowing of atrophy. The pre‐specified Mild group showed trends to HV atrophy slowing that did not translate to clinical benefits. The pre‐specified MCI group showed significant 28% HV atrophy slowing with meaningful cognitive and functional benefits and positive trends on several secondary clinical outcomes. Overall safety was favorable with no increased ARIA. In the high‐risk APOE4/4 population, this positive benefit‐risk profile supports valiltramiprosate’s potential as an oral disease‐modifying treatment for APOE4/4 homozygotes with MCI.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
APAidan Power
Aidan Power
DWDavid Watson
David Watson
SASusan Abushakra
Susan Abushakra
EMEmer MacSweeney
Emer MacSweeney
APAnton P. Porsteinsson
Anton P. Porsteinsson
MTMartin Tolar
Martin Tolar
Background: ALZ‐801/valiltramiprosate, an oral small molecule inhibitor of amyloid oligomer formation, is being evaluated in a Phase 3 trial in APOE4/4 Early AD subjects (APOLLOE4). Topline results are expected in 3Q 2024. APOE4 is a major risk factor for Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA) with a gene‐dose effect. APOE4/4 subjects with CAA are at higher risk of amyloid related imaging abnormalities (ARIA) with anti‐amyloid antibodies, including ARIA‐E (effusion/edema) and ARIA‐H [lobar microhemorrhages (MH), macrohemorrhages, and superficial siderosis (SS)]. APOE4 carriers are also at higher risk of hyperlipidemia and cardiovascular disease (CVD). Baseline prevalence of CAA and CVD risk factors were analyzed.Method: This Phase 3 trial (NCT04770220) enrolled 325 APOE4/4 Early AD subjects (MMSE ≥22, 50‐80 years); 313 had baseline MRIs with central readings. Subjects with MH and SS were enrolled; ARIA‐E was exclusionary. Subjects with CAA (>4 MH, any siderosis, any macrohemorrhage) were compared to rest of population.Result: Study population was 51% female, age 69 years, MMSE 26, 65%/MCI, 82% Caucasians. CAA group included 47/313 subjects (15%) of study, was mostly male (70% vs 45%), older (71 vs. 68 years, p = 0.004), more advanced (MMSE 25 vs 26, p = 0.018; ADAS‐cog 27 vs. 23, p = 0.002) with more severe deep WMD (p = 0.015). Both groups had similar prevalence of hypertension, diabetes, obesity, hyperlipidemia, and statin use but with higher coronary artery disease prevalence (17% vs. 8%, p = 0.049) and anti‐platelets use (38% vs 22%, p = 0.026) in the CAA group. No anticoagulants were allowed.Conclusion: ALZ‐801 showed no ARIA‐E in prior AD studies allowing its evaluation in the high‐risk APOE4/4 homozygotes. This pivotal APOLLOE4 Phase 3 trial of ALZ‐801 enrolled homozygous APOE4/4 subjects with higher CAA burden than anti‐amyloid antibody trials. The APOE4/4 CAA subjects were older with more advanced AD and higher rates of CAD and antiplatelets use than non‐CAA subjects, which may increase brain edema and microhemorrhage risk, requiring heightened vigilance with anti‐amyloid antibodies. If this Phase 3 trial is positive, ALZ‐801 could become a potentially safer alternative to anti‐amyloid antibodies for this population. The Phase 3 results are expected in 3Q 2024.